• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

With 3M's Lower Fundamental Price Target, What Do the Charts Say?

Let's see where MMM is going now.
By BRUCE KAMICH
Apr 04, 2022 | 03:18 PM EDT
Stocks quotes in this article: MMM

Barclays lowered their price target for 3M (MMM) from $170 to $155 Monday as they see demand headwinds for 3M's products. Let's check out the charts and indicators to see where MMM may be going from here.

 
In our December 14 review we wrote that "MMM has reached a Point and Figure price target and there is a bullish divergence between the price action and the momentum study. I like this 'set up' and would suggest to aggressive traders to go long MMM at current levels. Risk a close $169 or a new low close for the move down. Add to longs above $186." Unfortunately the price of MMM only steadied itself into January and then proceeded to sink to new lows.
 
In this daily bar chart of MMM, below, we can see that prices found some buying interest (support) near $140. MMM made a shallow bounce towards the underside of the declining 50-day moving average line. The slope of the slower-to-react 200-day moving average line is negative. The trading volume looks like it has been heavier than average the past five weeks or so.
 
This increase in turnover looks to be a positive development but the daily On-Balance-Volume (OBV) line shows a decline and a recovery. The daily Moving Average Convergence Divergence (MACD) oscillator has improved from late February but is still below the zero line and not an outright buy.
 
 
In this weekly Japanese candlestick chart of MMM, below, we see a bearish picture. Prices are in a downtrend and trade below the declining 40-week moving average line. I do not see any bottom reversal patterns.
 
The weekly OBV line has been weak since August. The MACD oscillator is bearish but showing some narrowing.
 
 
In this daily Point and Figure chart of MMM, below, we can see a potential upside price target of $173.
 
In this weekly Point and Figure chart of MMM, below, we can see the same $173 price target.
 
Bottom line strategy: I do not see a bearish setup for MMM right now, however the bull case needs further development. I would stand aside for now and let the bulls and bears battle it out a little longer.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Household Products | Industrial Goods | Analyst Actions

More from Investing

Welcome to Second Semester on Wall Street, Here's How to Make the Grade

Jim Collins
Jul 1, 2022 4:36 PM EDT

Think you can own big tech? You might just get an 'F' for that. Here's what will get you on the other side of this year.

We Got a Break, but the Heat Is Still On

James "Rev Shark" DePorre
Jul 1, 2022 4:22 PM EDT

A limited rally cooled some of the negativity on the market, but guess what's going to hit the fan soon?

Coupang Could Make a Bigger Trading Bounce

Bruce Kamich
Jul 1, 2022 1:56 PM EDT

Here's where nimble traders could probe the long side.

Does Halozyme Therapeutics, My Q2 Pick, Still Have a HALO Over It?

Bruce Kamich
Jul 1, 2022 1:13 PM EDT

Let's check the charts on this biotechnology stock and see if it still has a prayer.

Shares of Xencor Could Be Bought on a 50% Correction

Bruce Kamich
Jul 1, 2022 11:59 AM EDT

Traders should remain patient.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login